Evaluating Dalbavancin Suppression Therapy in Patients at High Risk for Recurrent Infections.

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Pharmacy

Background:

• Dalbavancin, a lipoglycopeptide antibiotic, is increasingly used off-label for deep-seated infections.
• Limited data exist on its use for suppressive antibiotic therapy (SAT).

Purpose of the Study:

• To characterize real-world dalbavancin dosing strategies for SAT.
• To assess the safety and efficacy of dalbavancin in SAT.

Main Methods:

• A multicenter, multinational, retrospective descriptive study.
• Included adult patients receiving dalbavancin SAT between January 2018 and March 2023.
• Primary endpoint: description of dosing strategies; secondary endpoints: TEAEs and clinical failure.

Main Results:

• Forty-six patients received dalbavancin SAT for a median of 201 days, often with retained devices.
• The most frequent dosing was 1500 mg IV every 2 weeks.
• 45.7% experienced TEAEs (most common: acute kidney injury), with rare discontinuation. 17.4% experienced clinical failure.

Conclusions:

• This study represents the largest cohort of dalbavancin SAT to date.
• Dalbavancin demonstrated feasibility and acceptable outcomes for SAT, with low rates of clinical failure and adverse event discontinuation.
• Further research is needed to optimize dalbavancin dosing and evaluate long-term safety for SAT.